Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase - inhibitors a single center experience

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase - inhibitors a single center experience

Beatriz Felicio Ribeiro, Eliana C. M. Miranda, Dulcineia Martins de Albuquerque, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergilio, Rosana Antunes Da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A. De Souza, Katia B. B. Pagnano

ARTIGO

Inglês

To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. Bone marrow karyotyping...

Aberto

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase - inhibitors a single center experience

Beatriz Felicio Ribeiro, Eliana C. M. Miranda, Dulcineia Martins de Albuquerque, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergilio, Rosana Antunes Da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A. De Souza, Katia B. B. Pagnano


										

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase - inhibitors a single center experience

Beatriz Felicio Ribeiro, Eliana C. M. Miranda, Dulcineia Martins de Albuquerque, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergilio, Rosana Antunes Da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A. De Souza, Katia B. B. Pagnano

    Fontes

    Clinics

    Vol. 70, no. 9 (Aug., 2015), p. 550-555